(Total Views: 417)
Posted On: 02/16/2019 10:47:38 AM
Post# of 15624
205MM outstanding shares from +47.7MM common not registered yet.
I may have jump to conclusion here. not a done deal on all 47.7MM.. sale from time to time. just a bit odd that this filing filed on the same week as the RS announcement.
sorry guys, I'm out of my mind lately. After holding 2+ years and you expect your patience will be paid off. more drama on the horizon
https://ih.advfn.com/stock-market/USOTC/owc-p...24b3-424b3
"47,500,000 Shares of Common stock
This prospectus supplement no. 4 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our common stock by the selling stockholder of OWC Pharmaceutical Research Corp. named in the Prospectus. The number of shares offered for sale by the selling stockholder consists of up to (i) 140% of the 25,000,000 shares (or 35,000,000 shares) of our common stock currently issuable upon the conversion of 500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”) held by the selling stockholder and (ii) 12,500,000 shares of our common stock currently issuable upon exercise of warrants held by the selling stockholder (the “Warrants”). The selling stockholder acquired the Preferred Shares and the Warrants from us pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”), dated April 30, 2018, by and between the Company and the investor identified therein (the “Investor”)."
I may have jump to conclusion here. not a done deal on all 47.7MM.. sale from time to time. just a bit odd that this filing filed on the same week as the RS announcement.
sorry guys, I'm out of my mind lately. After holding 2+ years and you expect your patience will be paid off. more drama on the horizon
https://ih.advfn.com/stock-market/USOTC/owc-p...24b3-424b3
"47,500,000 Shares of Common stock
This prospectus supplement no. 4 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our common stock by the selling stockholder of OWC Pharmaceutical Research Corp. named in the Prospectus. The number of shares offered for sale by the selling stockholder consists of up to (i) 140% of the 25,000,000 shares (or 35,000,000 shares) of our common stock currently issuable upon the conversion of 500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”) held by the selling stockholder and (ii) 12,500,000 shares of our common stock currently issuable upon exercise of warrants held by the selling stockholder (the “Warrants”). The selling stockholder acquired the Preferred Shares and the Warrants from us pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”), dated April 30, 2018, by and between the Company and the investor identified therein (the “Investor”)."
(0)
(0)
